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Abstract 23 
Subheadings: The effective treatment of Acanthamoeba infections is complicated by the 24 
resistant cyst stage in the life cycle of these opportunistic parasitic protozoans. In previous 25 
studies, we demonstrated the high activity of statins and voriconazole against clinical 26 
strains of Acanthamoeba.  27 
 Objective: this study aimed to evaluate the evaluation of the combination of several 28 
statins (atorvastatin, fluvastatin and simvastatin) and various azoles (voriconazole, 29 
posaconazole and itraconazole) against Acanthamoeba spp.  30 
Methods: The efficiency of the differents drugs combinations against the trophozoite 31 
stage of different Acanthamoeba strains was evaluated by Alamar Blue assay. Neverless, 32 
the effect on the cyst stage was made by Inverted Microscope. As for the cytotoxicity of 33 
these combinations of azoles and statins was evaluated by measuring the release of lactate 34 
dehydrogenase from a murine macrophage cell line.  35 
Results: We found that combinations of any of the tested statins and voriconazole or 36 
posaconazole were more efficient at inhibiting Acanthamoeba compared to statins or 37 
azoles when tested individually. We found lower toxicity of these drug combination at 38 
the combined IC50s compared to that of the compounds alone. 39 
 Conclusions: We report that the combination of statins together with voriconazole and 40 
posaconazole is more efficient than these drugs by themselves, and these combinations 41 
have lower cytotoxicity in mammalian cell lines. 42 
 43 
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1. Introduction 47 
Among several genera of free-living amoebae, Acanthamoeba genus are responsible for 48 
different diseases such as, “Acanthamoeba Keratitis” (AK),  a sight-threating ulceration 49 
of the cornea, Granulomatous Amoebic Encephalitis (GAE) and various disseminated 50 
infections (mostly cutaneous). [1, 2] Current therapy against AK is based on topical 51 
applications of antimicrobials including various combinations of propamidine isethionate 52 
and neomycin or biguanides. [1, 2] However, Acanthamoeba can form a double wall cyst 53 
stage which is highly resistant to external agents including those mentioned above which 54 
significantly complicates therapy. [3] This means that there is an urgent need to discover 55 
drugs and drug regimens that are active against both trophozoites and cysts of 56 
Acanthamoeba [1, 2, 4-6].  57 
Statins are hypolipidemic agents widely used to lower the cholesterol levels and to 58 
prevent atherosclerotic cardiovascular disease. [7] Our previous studies have also 59 
demonstrated the in vitro efficacy of statins against Acanthamoeba trophozoites and cysts, 60 
highlighting them as a novel effective therapeutic approach against these pathogens. [5] 61 
Another agent which has shown high activity against both trophozoites and cysts of 62 
Acanthamoeba is voriconazole. [6, 8]  Voriconazole belongs to the triazole family which 63 
has been shown to inhibit 14-α-demethylase resulting in the reduced production of 64 
ergsoterol in Acanthamoeba. [9] Ergosterol and 7-dehyrostigmasterol have been reported 65 
as the major sterols presented in Acanthamoeba. [10, 11] The high efficacy of 66 
voriconazole against Acanthamoeba strains in vitro and in clinical cases has been reported 67 
in previous studies. [6, 8, 12] Other members of the family of triazoles that have been 68 
used as antifungals are posaconazole and itraconazole. Posaconazole has been previously 69 
reported to have a wide microbial activity spectrum and has recently been evaluated 70 
against Acanthamoeba cysts in vitro. [9, 13] Although itraconazole, has been included in 71 
successful treatment combinations against skin lesions caused by Acanthamoeba, it is 72 
reported to be less active compared to other azoles. [3, 14] In many cases combinations 73 
of therapeutic drugs are found to be more efficient than the individually applied drugs. In 74 
the case of Acanthamoeba, this phenomenon has been recently demonstrated recently 75 
using combination of biguanides. [4] 76 
Although the activity of statins and triazoles has been already described against 77 
Acanthamoeba strains, they have not been tested in combination. In the present study, 78 
combinations of these molecules were tested for their amoebicidal and cysticidal activity 79 
as well as for their cytotoxicity in a mammalian cell line. We report that these drugs are 80 
more efficient in combination, which suggests a better approach for the treatment of 81 
Acanthamoeba infections. 82 
2. Materials and Methods 83 
2.1. Acanthamoeba strains.  84 
We have used three Acanthamoeba isolates in this study. One type strain Acanthamoeba 85 
castellanii Neff (ATCC 30010, genotype T4) and two clinical strains previously isolated 86 
by our group CLC-16, (genotype T3) and CLC-51. l (genotype T1). [15] All strains were 87 
culture axenically at room temperature in PYG medium supplemented with 40 g/ml 88 
gentamicin (Sigma-Aldrich Chemistry Ltd., Madrid, Spain).  89 
2.2. Chemicals.  90 
The azoles posaconazole and voriconazole were purchased from Sigma-Aldrich 91 
Chemistry Ltd. (Madrid, Spain) and itraconazole was purchased from the Cayman 92 
Chemical Company (Vitro, Madrid, Spain).  Simvastatin, atorvastatin, and fluvastatin 93 
were from the Cayman Chemical Company. 94 
2.3. Activity assays.  95 
The anti-Acanthamoeba activities of the drugs were determined by the AlamarBlue® 96 
assay, as previously described. [15, 16] Briefly, 50l of Acanthamoeba trophozoite cells 97 
(104 cells/ml) were seeded in 96-well microtiter plates. Amoebae were allowed to adhere 98 
for 15 min and 50 μl of different dilutions of the drugs in were then added. Finally, 10µl 99 
of the Alamar Blue Assay Reagent (Bioresource, Europe, Nivelles, Belgium) to each well. 100 
Plates were then incubated up to 120 h at 28°C with slight agitation and measured using 101 
an EnSpire® Multimode Plate Reader (Perkin Elmer, Madrid, Spain). We used a test 102 
wavelength of 570 nm and a reference wavelength of 630 nm. Inhibitory concentration  103 
50% (IC50) and 90% (IC90) were calculated by non-linear- regression analysis with 95% 104 
confidence limits. The IC50s of each drug alone was calculated and drug combinations 105 
were then tested at various concentration to determine the lowest IC50s of each drug 106 
combination. 107 
2.4. Evaluation of the cysticidal activity of posaconazole.  108 
The effects of posaconazole against cysts were evaluated against the three strains of 109 
Acanthamoeba. Mature cysts were prepared as previously described. [17] Briefly, 110 
trophozoites were transferred from PYG medium to Neff’s encystment medium (NEM) 111 
where they were cultured for a week under slight agitation to obtain mature cysts. After 112 
that, the cells were harvest and washed twice with PYG medium. A concentration of 104 113 
cysts/ml was transferred to plates containing fresh PYG medium and incubated with 114 
posaconazole at the previously calculated IC50s and IC90s. A Neubauer chamber, was used 115 
to count the number of of trophozoites, cysts, and non-viable each 24 hours for a week as 116 
previously described by Martín-Navarro et al, 2013a; 2013b. [5, 6] A negative control 117 
including only mature cysts in Neff’s encystment medium was included to the 118 
experiments. After 7 days of incubation, the supernatant was replaced with fresh PYG 119 
medium and the cultures were observed for a second week to confirm the cysticidal 120 
activity. 121 
2.5. Cytotoxicity evaluation.  122 
The murine macrophages cell line (ATCC TIB-67) was used to measure the cytotoxicity 123 
of the drugs individually and in combinations. This assay was evaluated by the measure 124 
of the release of lactate dehydrogenase by Cytotoxicity Detection Kit (LDH) (Roche 125 
Applied Science, Barcelona, Spain) was used, according to the manufacturer’s 126 
instructions. Levels of cytotoxicity less than 10 % were considered as being non-127 
cytotoxic, levels between 10–25 %, low toxicity, levels between 25–40 %, medium 128 
toxicity and higher than 40 %, highly cytotoxic.  were compared by one-way ANOVA 129 
using Sigma Plot 12.0 software (Systat Software Inc., London, UK). [2, 18]. 130 
2.6 statistical analysis 131 
All experiments were performed three times each in duplicate. Data were analysed using 132 
ANOVA, multiple post-hoc analysis, Tukey´s test and a paired two-tailed t-test and p 133 
values of <0.05 were considered significant. Statistical analysis was done with the Sigma 134 
Plot 12.0 software program (Systat Software Inc., London, UK).  135 
3. Results  136 
All three of the Acanthamoeba strains tested were found to be sensitive to the statins, 137 
posaconazole and voriconazole (Table 1), but the activity of itraconazole was low and 138 
this drug was not used in further experiments.  All combinations of statins and 139 
voriconazole and posaconazole were active against the strains of Acanthamoeba. 140 
However, the different drug combined, produce lower IC50s compared to the IC50 of the 141 
molecules alone (Table 2 and 3). The cysticidal activity of posaconazole was also 142 
evaluated and found to reduce the viability of all three strains. The IC50 and IC90 of 143 
posaconazole for cysts was calculated (Figure 1). After 168 h no cysts were able to revert 144 
into trophozoites.  145 
We tested the toxicity of the drugs, simvastatin IC50 (S50), posaconazole IC50 (P50), 146 
voriconazole IC50 (V50) and the following combinations of molecules: posaconazole and 147 
atorvastatin (P + A), posaconazole and fluvastatin (P + F), posaconazole and simvastatin 148 
(P + S), and voriconazole with atorvastatin, fluvastatin and simvastatin (V + A, V + F and 149 
V + S) did not induce cytotoxicity against macrophages. Whereas in the case of 150 
atorvastatin IC50 and IC90 (A50 and A90), fluvastatin IC50 and IC90 (F50 and F90), 151 
posaconazole IC90 (P90) and voriconazole IC90 (V90), low cytotoxicity values against 152 
macrophages were observed. Furthermore, moderate toxicity was shown in the case of 153 
cells incubated with simvastatin IC90 (S90) and Amphotericin B IC90 (AnfB90) and 154 
chlorhexidine IC90 (Chx90), induced high levels of toxicity in the tested cell line (Figure 155 
2). The statistical analysis revealed statistical differences (p < 0.001) in the cytotoxicity 156 
produced by the reference drugs (IC90 of Chx and AnfB) and all treatments, excepting in 157 
the comparison between Chx90 and S90 (Figure 2).  158 
4. Discussion 159 
Drugs are often combined in the hope that their activities synergize to increase their 160 
therapeutic potency. There are many instances where this applies (e.g. HIV therapy) and 161 
this has also been found with Acanthamoeba, where polyhexamethylene biguanide 162 
combined effectively with chlorhexidine. [4] This has also been found with various other 163 
drug combinations. [19] It is also an advantage if the cytotoxicity produced by this 164 
combination will be the same or even lower than that produced by the individual drugs 165 
themselves. Such a decrease in the toxicity has been reported by the combination of 166 
PHMB and chlorhexidine on epithelial cells. [4] 167 
Statins and voriconazole were used in this study because of their proven amoebicidal and 168 
cysticidal activity and their relatively low cytotoxicity. The activity of atorvastatin, 169 
fluvastatin, simvastatin and voriconazole against Acanthamoeba was previously 170 
evaluated by our group. [5, 6, 8, 16] These in vitro results can be compared with in vivo 171 
experiment were voriconazole has been successfully used to treat amoebic infections, 172 
even against resistant Acanthamoeba strains. [12] Initially, those drugs were chosen 173 
because their molecular target, ergosterol was known to be a valid one. Statins inhibit 3-174 
hydroxy-3-methylglutaryl–coenzyme A (HMGCoA) reductase, an enzyme that catalyse 175 
the conversion of HMG-CoA to mevalonate, which is a precursor of cholesterol in 176 
vertebrates and ergosterol in fungi and some protozoa such as Acanthamoeba. [5, 20] 177 
Voriconazole, it is a triazole antifungal agent that causes demethylation of ergosterol. As 178 
both drugs act to inhibit different parts of the same ergosterol pathway, we suspected that 179 
these two drugs may be combined successfully. 180 
Itraconazole has been included in some successful treatment regimens used against skin 181 
lesion in a lung transplant patient with disseminated acanthamoebiasis and against 182 
Acanthamoeba keratitis. [14, 21] However, resistance to azoles has been reported. 183 
Acanthamoeba from skin nodules of a fatal cutaneous infection in an HIV patient, was 184 
resistant to a combination of drugs with itraconazole in vitro. [21] We confirm that only 185 
a weakly amoebicidal effect of itraconazole and, because of this, it was discarded for 186 
further experiments. We could find only one study in which posaconazole, has been used 187 
against Acanthamoeba, showing a cysticidal activity in clinical and culture collection 188 
isolates . [9] This previous study reported minimal cysticidal concentrations (43.75 - 52.5 189 
M) that are higher than the IC50 found in the present study (2.56 -7.50 M). 190 
We have reported that statins and voriconazole lead to the death of Acanthamoeba by the 191 
activation of programmed cell death. [8] We have also reported that caffeine and maslinic 192 
acid also activate programmed cell death but we do not yet know the molecular targets of 193 
either drug. It remains to be seen if either caffeine or maslinic acid treatment will allow 194 
even lower concentrations of statins, posaconaole or voriconazole to be effective in 195 
human therapy. [18] 196 
5. Conclusion 197 
We report that the combination of statins together with voriconazole and posaconazole is 198 
more efficient than these drugs by themselves, and these combinations have lower 199 
cytotoxicity in mammalian cell lines. We anticipate that treatments based on 200 
combinations of statins and azoles will be more effective and better tolerated than present 201 
treatment regimens against Acanthamoeba infections of humans. 202 
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FIGURE LEGENDS: 297 
 298 
Figure 1. Number of cysts when they were incubated with posaconazole with previously 299 
calculated IC50 and IC90 in PYG medium. Cysts were not viable after incubation with this 300 
drug, since amoebae were not able to excyst. Moreover, the number of cysts decreased 301 
with time and became non-viable cells.  302 
 303 
Figure 2. Cytotoxicity of atorvastatin, fluvastatin, simvastatin, posaconazole, 304 
voriconazole, amphotericin B and chlorhexidine at IC50 and IC90 as well the combination 305 
between azoles and statins produced in murine macrophages. A50 and A90: atorvastatin 306 
IC50 and IC90. F50 and F90: fluvastatin IC50 and IC90. S50 and S90: simvastatin IC50 and 307 
IC90. P50 and P90: posaconazole IC50 and IC90. P + A: posaconazole and atorvastatin. P 308 
+ F: posaconazole and fluvastatin. P + S: posaconazole and simvastatin. V50 and V90: 309 
voriconazole IC50 and IC90. V + A: voriconazole and atorvastatin. V + F: voriconazole 310 
and fluvastatin. V + S: voriconazole and simvastatin. AnfB50 and AnfB90: amphotericin 311 
B IC50 and IC90. Chx50 and Chx90: chlorhexidine IC50 and IC90. The results showed that 312 
S50, P50, V50 and the following combinations: P + A, P + F, P + S, and V + A, V + F 313 
and V + S were not cytotoxic against macrophages. A50 and A90, F50 and F90, P90 and 314 
V90 presented low cytotoxicity against macrophages. The observed cytotoxicity levels 315 
were moderate when cells were incubated with S90. AnfB90 and Chx90 showed high 316 
levels of cytotoxicity against macrophages. The cytotoxicity values showed significant 317 
differences with the cytotoxicity produced by the reference drugs chlorhexidine and 318 
amphotericin B (***, p<0.001).  319 
 320 
  
Table 1. IC50 and IC90 (M) values for posaconazole against different strains of Acanthamoeba measured by Alamar blue assay after 96h (Mean 321 
concentration ± SD). 322 
 323 
 324 
 325 
 326 
IC50 (M) 96h AcNeff CLC-16 CLC-51.l 
 IC50 IC90 IC50 IC90 IC50 IC90 
Atorvastatin 15.12 ± 2.19 41.09 ± 0.01 33.34 ± 2.64 78.66 ± 5.85 26.63 ± 1.20 49.76 ± 1.81 
Fluvastatin 9.19 ± 0.98 20.70 ± 2.15 54.64 ± 2.69 105.40 ± 5.34 16.50 ± 1.03 32.86 ± 5.18 
Simvastatin 10.24 ± 1.09 21.37 ± 1.51 31.44 ± 2.06 63.55 ± 4.15 39.73 ± 4.34 84.16 ± 8.23 
Voriconazole 13.14 ± 0.69 30.43 ± 1.32 21.93 ± 5.87 44.18 ± 11.46 13.31 ± 1.69 30.01 ± 3.93 
Posaconazole 3.03 ± 0.32 5.78 ± 0.02 2.56 ± 0.28 16.53 ± 1.49 7.50 ± 0.39 23.53 ± 1.35 
Itraconazole 59.32 ± 0.78 196.65 ± 13.32 75.45 ± 4.15 151.62 ± 6.11 113.73 ± 10.80 219.09 ± 11.22 
  
Table 2. IC50 (M) values for voriconazole and each statin assayed when this compounds were combined and evaluated against different strains of 327 
Acanthamoeba measured by Alamar blue assay after 96h (Mean concentration ± SD). (***) p ≤ 0.001 statistical differences between those values 328 
and the IC50 of each product alone. 329 
IC50 (M) 96h V + A V + F V + S 
 
Voriconazole Atorvastatin Voriconazole Fluvastatin Voriconazole Simvastatin 
AcNeff 1.63 ± 0.11*** 1.71 ± 0.13*** 1.00 ± 0.09*** 0.97 ± 0.09*** 1.00 ± 0.03*** 0.97 ± 0.07*** 
CLC-16 8.96 ± 0.89*** 12.50 ± 1.24*** 4.18 ± 0.34*** 3.88 ± 0.32*** 7.67 ± 0.20*** 7.08 ± 0.15*** 
CLC-51.l 6.50 ± 0.20*** 9.09 ± 0.27*** 6.98 ± 0.09*** 6.52 ± 0.09*** 6.07 ± 0.20*** 5.65 ± 0.18*** 
 330 
 331 
  
Table 3. IC50 (M) values for posaconazole and each statin assayed when this compounds were combined and evaluated against different strains 332 
of Acanthamoeba measured by Alamar blue assay after 96h (Mean concentration ± SD). (***) p ≤ 0.001 statistical differences between those values 333 
and the IC50 of each product alone.  334 
IC50 (M) 96h P + A P + F P + S 
 Posaconazole Atorvastatin Posaconazole Fluvastatin Posaconazole Simvastatin 
AcNeff 0.65 ± 0.04*** 1.79 ± 0.27*** 2.27 ± 0.15*** 6.05 ± 0.41*** 2.17 ± 0.09*** 5.79 ± 0.24*** 
CLC-16 3.75 ± 0.40*** 14.09 ± 1.60*** 0.62 ± 0.04*** 1.66 ± 0.11*** 3.00 ± 0.20 8.01 ± 0.54*** 
CLC-51.l 2.04 ± 0.03*** 8.17 ± 0.13*** 2.23 ± 0.17*** 5.94 ± 0.45*** 1.78 ± 0.09*** 4.76 ± 0.24*** 
 335 
